TWI363621B - Antiviral composition - Google Patents

Description

1363621 •- Nine, invention description: [Technical field to which the invention pertains]; The present invention relates to an antiviral agent. [Prior Art] The virus system is incapable of self-propagating and parasitic to the extremely small pathogens of animals, plants or bacteria, and can be classified into animal viruses, plant viruses, and microbial viruses. Human cytomegalovirus is highly specific and does not proliferate in cells other than human-derived cells. For the proliferation, various primary cultured cells such as human skin, muscle, foreskin, and lung, or - established cells such as -MRC-5 and WI-38 can be used. An intranuclear inclusion body (intestinal) and a cytoplasmic inclusion body can be confirmed in the infected cells. Transplacental infection (vertical infection) is the cause of stillbirth, premature birth, and causes congenital infection (CID, also known as cytomegalic inclusion disease, giant cell inclusion body disease). It is also considered as an acquired infection. At this time, it is generally caused by immunosuppressive therapy, steroid use, and AIDS patients or cancer patients after inapparent infection. Infectious hosts are activated, causing serious opportunistic infections such as pneumonia, retinitis, and colitis. Antiviral agents for the prevention and treatment of diseases caused by such viruses are under development. For example, Ganciclovir (i.e., GCV), Cidofovir (i.e., CDV), foscarnet (i.e., PFA), and Fomivirsen are known. Among them, GCV is widely used, 5 320044 1363621 •• However, in recent years, the GCV-resistant virus system has become a problem. In addition, there is also a problem that the side effect (cytotoxicity) is strong, so that there is no side effect and there is a drug-resistant virus; and an effective antiviral activity is also required. / Influenza virus (also known as flu virus) is a virus that causes infection in humans, and causes influenza virus infections, including type A, type B, and type C. In addition, some of the influenza viruses infect chickens and other poultry and cause highly pathogenic avian influenza (also known as chickens), which are both fatal and legal infectious diseases, causing great damage to the chicken industry. In 2006, there were three types of anti-avian flu drugs: amantadine, Zanamivir, and Oseltamivir (trade name: Tamiflu). . On the other hand, the amantadine-resistant influenza virus 'Zanamivir (Oxemide)-resistant influenza virus resistant to these agents, for zanamivir and oseltamivir The emergence of a drug-resistant virus has also been reported. • Therefore, a drug system that has no side effects and has an antiviral activity that is also effective against a drug-resistant virus is in demand. On the other hand, 'Bamboo grass extracts are known to have antibacterial properties. For example, the antibacterial effect of Staphylococcus aureus, Pdeudomonas aeruginosa, and Escherichia coli against bacteria belonging to the cause of traumatic infection has been reported (Patent Document 1 and Patent Document 2) ), or the antibacterial effect of Helicobacter pylori, which is considered to be a cause of gastric ulcer. After the war, it was found in the animal experiment that Sasa veitchii has inhibitory activity against the liver cancer of the old 6 320044 1363621 • mouse, and many pharmacological studies have been carried out in the direction of carcinogenic activity (Non-Patent Document 1). In addition, it is excellent in the effect of the mountain white bamboo: the different anti-corrosion effect (Non-Patent Document 2) and the antibacterial effect (Non-Patent Document 3) have been studied. However, most of these studies are only organic acid analysis based on gas chromatography, and there are few reports on the separation and purification of the antibacterial effect body. It is also known that coumaric acid and its derivatives have antibacterial properties against colonic bacteria, Staphylococcus aureus, and Pseudomonas aeruginosa (Patent Document 3). In addition, it is also known that the extract of the white bamboo contains coumaric acid, ferulic acid, coffeic acid, vanillin, etc., and hydroxypyrazole. The mixture is antibacterial to Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa (Patent Document 4). However, the details of each component in the extract of the white bamboo extract and its antiviral activity are still unknown. [Patent Document 1] WO00/067707 [Patent Document 2] JP-A-2003-201247 [Patent Document 3] JP-A-2004-359626 [Patent Document 4] JP-A-2006-36731 [Non-Patent Document 1] M. Shibata, K. Kubo, M. Onoda, Folia Pharmacol. Jpn, 72, 531-541 (1976) [Non-Patent Document 2] N. V· Chuyen, T. Kurata, H. Kato, J. Antibact. Antifung. Agents , 11, 69-75 (1983) [Non-Patent Document 3] NV Chuyen, H. Kato, Agric. Biol. Chem., 46, 2795-2801 (1982) 3-128 (2004) 7 320044 • [Summary of the Invention] (Question to be Solved by the Invention) - The object of the present invention is to provide an antiviral agent. 〉· & Another object of the present invention is to provide an antiviral agent having high antiviral activity and low side effects (fine cell preparation). (Method for Solving the Problem) The present invention provides an antiviral agent as described below: _ (1) An antiviral agent selected from the group consisting of 5, 7, 4, · trihydroxy _3, 5, dimethyl At least one of the group consisting of oxypage ketone, 3-hydroxypyridine, p-hydroxybenzaldehyde, and vanillin is used as an active ingredient. - (2) An antiviral agent which is an active ingredient of 5,7,4,-trihydroxy-3,5,-dimethoxy yellow or 3-hydroxyhistidine. (3) An antiviral agent which is an active ingredient of 5,7,4,3-trihydroxy-3,5,-dimethoxyxanthone. (4) The antiviral agent according to any one of the above (1) to (3) wherein the virus is a herpesvirus. (5) The antiviral agent according to any one of the above (1) to (3) wherein the virus is a cytomegalovirus. (6) The antiviral agent according to any one of (1) to (3) above, wherein the virus is a human cytomegalovirus. (7) The antiviral agent according to (3) above, wherein the virus is an influenza virus. (8) The antiviral agent according to (7) above, wherein the virus is an influenza A virus or a influenza B virus. (9) The antiviral agent according to (7) above, wherein the virus is an avian influenza virus. 320044 8 1363621 '* "Virus" in the present invention includes animal virus, insect disease I, plant virus, bacterial virus (phage), and especially refers to animals and plants including humans, animals, birds and the like, which cause bad The virus that affects. , * I antiviral agent can be particularly effective virus, such as blister, virus, influenza virus, in particular, such as cytomegalovirus, especially human dendritic virus, monkey cytomegalovirus, mouse giant cell A cytomegalovirus such as a virus, a human influenza virus such as influenza A virus, influenza B virus, or influenza C virus, or avian influenza virus. (Effects of the Invention) The antiviral agent of the present invention is specific for various viruses 'especially: herpes virus, especially cytomegalovirus, more particularly human cytomegalovirus; influenza virus, particularly influenza A virus, type B Influenza virus, influenza C virus or avian influenza virus has a high degree of antiviral activity. The antiviral agent of the present invention has the advantage of low cytotoxicity. [Embodiment] Φ In order to clarify the antibacterial effect of Sasa veitchii and to specify its antibacterial active ingredient, the inventors of the present invention fractionate the hot water extract of the mountain white bamboo leaves in various solvents and purify them by various separations. The method was isolated and purified, and the antiviral activity of each component was investigated. As a result, 5,7,4,-trihydroxy-3,5,-dioxaxyflavone (hereinafter also referred to as "Tricin"), 3-hydroxypyridine, p-hydroxybenzofural was found. And vanillin, which in turn is 5,7,4,-trihydroxy-3,5,1,dimethoxyflavone and 3-hydroxypyridine, especially 5,7,4,_trihydroxy-3, The 5,-dioxaxyflavone (i.e., scutellaria) exhibits excellent antiviral activity against various viruses, and the present invention has been completed by 9 320044 1363621. Hereinafter, the present invention will be specifically described. The active ingredient of the present invention 5,7,4'-trihydroxy-3,5,'-dimethoxy yellow/ketone, 3-hydroxypyridine, p-hydroxybenzaldehyde, and vanillin are from the mountain Extracted from white bamboo, but of course it can be synthetic or obtained from other sources. For example, plants other than the white bamboo are especially the majority of plants belonging to the Poaceae family, such as rice (rice), wheat, maize, barley, semale, sweet and sour, bamboo, Miscanthus, and pampas grass. Pampas grass), Phragmites and other grassy leaves or stems contain a large amount of 5,7,4,-trihydroxy-3',5,'-dimethoxy yellow g (also known as wheat yolk J), from which it can be extracted. The specific plant names are as follows: Rice, wheat, barley, oats, rye, Panicum miliaceum, Setaria italica, Echinochloa esculenta, maize, Eleusine coracana, sorghum (Sorghum bicolor), bamboo, yarrow (212 & 1^1wang 1^〇^), Gan Yan, 薏苡 (111 & -71^11), reed, Miscanthus, φ Bamboo grass, Luzhu ( Arundo donax), scutellaria, and Zoysiajaponica 〇 The leaves and stems of the above plants can be extracted with a suitable solvent, and the flavonoids can be isolated and purified by separation and purification methods such as HPLC. For example, the aqueous extract can be concentrated, and the solid matter is extracted with an alcohol, an aqueous alcohol (for example, methanol, ethanol, aqueous sterol, aqueous ethanol), and the solid is dissolved in water by using ethyl acetate. It can be refined by dispensing or the like. The above compounds (vanillin, p-hydroxybenzaldehyde, 3-hydroxypyridine, 5,7,4'-trisyl-3',5,'-didecyloxyxanthine) (also referred to in this specification) The antiviral agent of the present invention which is at least one of CS) 10 320044 1363621 + a compound of the invention") as an active ingredient can be used in various forms. For example, it is suitable for mucosal protection: an antiviral agent such as a composition, a viral infection prevention and/or therapeutic composition, a preservative, a filter, and a shelf. The antiviral agent of the present invention may be in the form of a liquid, a solid, a gas, a gel, a gel, or an aerosol. The antiviral agent of the present invention can be administered by oral administration or by any of the administration forms which are not administered orally. The two-component technology can be exemplified by a spinner, a pill, a powder, a liquid, a chewing gum, For food, beverage aqueous solutions, seasonings, etc., such as candy, chocolate candy, bread, biscuits, soba noodles, oolong noodles, etc.; non-oral administration forms such as injections, topical administration Agents (creams, ointments, etc.), suppositories, intravaginal administration (filling cotton balls (8), etc.). Examples of the dosage form of the topical administration agent include, for example, a carrier such as a gauze made of a ray or a synthetic fiber, which is impregnated with the antiviral agent of the present invention; a cosmetic such as a lipstick or other type of cosmetic (emulsion, oil, Soap, make-up Lu, water, cream, etc.) or bathing gel containing the antiviral agent of the present invention; semi-solid or liquid type such as cosmetic liquid, shampoo, shower gel, facial cleanser, etc. State and so on. It can also be made into eye-type agents, esthetics, and the like. For example, a spray for treating a wound site or a spray for treating a pharyngeal head inflammation may be mentioned. The antiviral agent of the present invention is effective as an antiviral agent for use in mammals, birds, fish and shellfish, crustaceans, insects, two-story, and insects, except for humans. . Therefore, the antiviral agent of the present invention can be used as the antiviral agent for the animal (for example, the pet doctor 320044 11 1363621 • the poison of the medicine, the animal feed, the pet food, etc., in addition to the anti-drug of the animal of the invention In addition, it is also used as a preservative for various plant anti-disease agents. The above::::: Anti-viral agents of various dosage forms, except for a predetermined amount of rot The water used in the base material such as the oil component such as the oil component and the humectant, water repellency, etc. can be tap water, natural water, or refined. It is particularly limited. However, high-purity water such as ion-exchanged water is used. The sexual ingredients may be, for example, tallow, eucalyptus oil, horse oil, lanolin, =:=physical oil; olive oil, grape seed oil, palm oil, jojoba oil, oil, etc., such as radish sesame oil), sesame oil,菜轩油' safflower oil, salad, oil, mobile paraffin, high-grade tartaric acid ester (such as palmitic acid bismuth, isopropyl palmitate, myristic acid Nai. a synthetic oil, semi-synthetic oil. Rattan of octyl ten-yard ester), Ju Shixi Oxygen Oil can match the skin It is used in combination with the protective effect and the emollient effect (the thin surface, the surface of the skin is covered, and the softness, elasticity ==), dryness, and the like are required to be combined. A combination of simmering, olive oil and octyl 12-filament of myristic acid is one of the preferred examples. In order to adjust the hardness and flow name of the antiviral agent, stearic acid, stearyl alcohol, behenie aeid, _alcohol ((10) solid oil such as chiagrass may be used, preferably hard fat is used in combination. Acid and feed alcohol. In order to manufacture the antiviral agent of the present invention into a cream composition, 12 can be used.

I (S 320044 • The compound, water and oily ingredients of the invention are made into a creamy creaming agent. The h-reducing agent is not #, and the general-purpose monostearic acid glycerin and self-single-stearic acid Glycerin (that is, an emulsifier added to monostearic acid glycerin) is used in combination. The antiviral agent of the present invention may also be used in combination with other antiviral agents. π is prepared in the hair growth antiviral agent, in order to meet the demand Further, it may contain a stabilizer, a wound healing agent, a preservative, a surfactant, etc. In terms of the stabilizer, one can be listed, for example, a carboxyvinyl polymer and potassium hydroxide, and a polyethylenol. Di-stearic acid ((polyethylene g) yC0l rteame)), especially polyethylene glycol sesquilique vinegar (four) kiss lene two „D qulstearate) (also known as polyethylene glycol distearate Ester and polyethyl; = mixture of fatty acid vinegar) (polyethylene glycol has a molecular weight of (10). 矣暮, because of its high stability' and water and oil will not separate, and the composition of the r can be effectively adjusted The hardness when applied to the skin is preferred. As far as the humectant is concerned, the stone, 丨 and ip are listed as glass. Sodium, collagen, aloe extract • (two from the aloe vera extract (7) is good), urea, two 'sea (four) Μ-), sorbitol, amino acid, tons of strontium and sodium sulphate. For the licorice healing agent, for example, allantoin, disodium glycyrrhizinate, early pregnancy, wormwood extract, etc. Preservatives are auxiliary materials. For example, for H, such as sodium benzoate, Low-grade benzoic acid _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ , sodium propionate, mixed fatty acid esters (glycew • aprate, lauric acid polyglyceryl ester 2, lauric acid polyglyceryl ester-10 mixed,,), phenoxyethanol, photoreceptor 201 (yellow pigment), 1,2-pentanediol ♦, etc., and further preferably p-hydroxybenzoic acid ester, mixed fatty acid ester, hydrazine, and 2-pentylene. In terms of surfactant, horse can be used as a surfactant. For example, sulfhydryl-L-glutamic acid sodium, small oxygen alpha-extension ethyl sorbitan monostearate, etc. may also contain aroma components, such as orange oil, as needed. Squeezing oil, spruce oil, spices, etc. The adhesive protective composition containing the antiviral agent of the present invention, the virus infection prevention and/or treatment (4) composition, can effectively inhibit the virus from the eyes, nose and throat , ear, anal fistula, vaginal material (4) or wound site and skin invading the body, and effectively prevent and / or treat viral infections including nosocomial infections. More specific aspects of viral sensation prevention and / or therapeutic composition The type may be, for example, a film protective cloth or an oral composition.

The mucosa protective cloth is made of a ventilating carrier by means of impregnation and spraying methods (for example, natural fibers such as silk, cotton, hemp, vitamins, polyamines, P〇lyUrethane, polyethylene, polypropylene, nylon). , polyester, acrylic synthetic fiber; semi-synthetic fiber; or a mixture of two or more of these fibers or the wire 'or its woven fabric, braided fabric, non-woven fabric, (four)) containing the compound of the present invention. For the sake of convenience, the "protective cloth" in this specification includes, in addition to the cloth, the fiber itself, the thread, the paper, and the like. In terms of the specific type, in addition to gauze cover, eye mask, menstrual belt, "eight. Nai, Ling Wang" sanitary napkins for menstruation, end belts, sanitary sputum, itch loyalty, s, acne treatment Use gauze and earplugs 320044 14 1363621 • Liquid enamel cream, etc., which are classified as sanitary products and directly contact the mucous membrane or skin. In addition to the protective cloth, clothes such as white clothes, gloves, hats, socks, and squat-foot bags are also listed. Small items such as socks, quilts, quilts, pillow covers, beds, etc., bedding, curtains, wallpapers, carpets, etc., interior decorations, interior materials, surgical materials, surgical sutures, etc. Or indirect contact with skin.

The oral composition containing the antiviral agent of the present invention may, for example, be a gummy, a jelly (jdly), a gradual tablet (tr〇che), a candy puff/chewing gum, a chocolate candy, a lozenge or a pill. A mouthwash, a mouthwash, a toothpaste, a film attached to a mucous membrane, a spray for treating pharyngeal inflammation, and the like. The antiviral agent of the present invention has high antiviral activity, and the compound of the present invention exhibits antiviral activity only at a solid concentration of from about 1 to about 1 ppm. When the antiviral agent of the present invention is used in a human, as long as the symptoms, age, and body weight are considered, the adult will be i to 5 mg, preferably 5 2000 mg, more preferably 10 to 1000, per day, or 1 time. It is divided into 2 to "can be administered left and right. To make, for example, soft rubber, east rubber, gradual coating agent, candy, chewing gum, gram sugar, lozenge 'pill (such as #), mouthwash, 漱The mouth composition, the film attached to the mucous membrane, and the like, which are contained in the oral composition, are required to be used in the manufacture of the oral composition, so that the amount of the substance can be added to the oral composition. The solid matter of the compound of the present invention is preferably added to about 1% by mass. More preferably, it is 6 to 320,044, and 15 1363621 is preferably 8 to 仏(10)1 to ίο·5)% by mass. For the dosage form of the poison, exemplify ^ rdry svrun'l > ^ , capsules, dry syrup t, pills, powders, liquids, such as lingluo and gel, oral spray, ·_ ·- Use nasal preparations, ointments, milk or pharyngeal direct preparations. These can be prepared according to common methods. System:: The base ingredient of the above-mentioned antiviral agent is dilactose, strict sugar, dextrin, cyclodextrin, starch, etc.: 'Arabic gum, methyl cellulose, crystalline cellulose, gum base A binder such as a gum base; a disintegrant such as starch; a lubricant such as stearic acid fatty acid ester; a fragrance, a sputum, a sputum, a thorn, a stalk, a phlegm, a thick, a 1-menthol The brain is equal to π θ , higher alcohol such as dodecyl alcohol; fatty acid vinegar such as isopropyl myristate, diisopropyl adipate and isopropyl palmitate; polysorbate (10) and polyemulsion Emulsifying agent such as ethyl hardened broad sesame oil; macromolecular polymers such as ethylene glycol, hydroxypropyl cellulose, polyvinyl ketone and sodium urate; glycerin, propylene glycol and U·butanediol a pH adjuster such as a polyhydric alcohol; diisopropanolamine, sodium hydroxide, potassium dihydrogen phosphate or sodium hydrogen phosphate; sodium hydrogen phosphate, sodium chloride, sodium thiosulfate, sodium sulfite, and sodium edetate ( Sodium edetate) and other stabilizers; methyl p-hydroxybenzoate, p-hydroxybenzoic acid, ammoniated benzate (benzaIk〇nium chI〇dde And a preservative such as chlorinated benzethonium chloride. When the antiviral agent of the present invention is used in the form of a protective cloth, the protective cloth (gauze, etc.) contacting the mucous membrane or the wound site is included. The invention can be replaced by one to three times a day. When used in the surgical suture. 320044 16 1363621 type, it can effectively inhibit the disease and promote the recovery of the surgical site. (4) When the antiviral agent of the present invention is used to prevent infection in hospitals such as hospitals and to protect the cloth, the disease resistance of the present invention may last for a long period of time. When i feels the wood b. When the effect is lowered, it is only necessary to replace the (four) cloth or the treatment of the compound. Human 3 has the invention: when the antiviral agent of the present invention is used as an oral composition, it can be extremely easily pre-prepared by pre-existing it in the mouth: "and inhibiting virus proliferation.", chewing gum It is advantageous that the composition of the present invention can be used for a long period of time. The antiviral agent of the present invention can also be used in the form of an emulsion or an oil. The solid content is 2 to 20 预先 (5) in advance. !·5 to 5% by mass. The emulsion or oil containing the compound of the present invention is applied to the skin or the like to prevent viral infection and inhibit virus proliferation in an extremely simple manner. The present invention also provides a method for containing the present invention. The compound of the invention is used as an active ingredient in an air-passing device. For specific types, it can be exemplified, for example, for use in changing fans, air conditioning equipment, automobile air conditioning equipment, air intake, air discharge, 'self-cleaning, air cleanliness The filter for passing the air through the machine, etc. The substrate of the filter is not particularly limited, and examples thereof include silk, cotton, wool, hemp, etc.; polyamine phthalate, polyethylene, polypropylene, and nylon. Synthetic fibers such as polyester or acrylic; semi-synthetic fibers; or woven fabrics, fabrics, non-woven fabrics, papers, etc. of a mixture of two or more of these, as long as they are compared by Western blotting by impregnation and spraying 320044 17 1363621. Reviewing the performance of viral proteins, especially the very important early-stage protein (immediate·^ pr〇tein) that plays a role in the post-infection (4) expression and works as a trigger protein for viral replication (tngger pn) tein) ), as well as the performance of advanced proteins such as synthetic enzymes, to compare the effects of each sample.

The cytopathic effect of the extract of the white bamboo extract (twebs (the solid concentration of 5 〇 mass (10)) is shown in Fig. 1 and the inhibitory effect of virus proliferation is shown in Fig. 2. Both the delinquent strain and the (5) R strain confirmed the effect of inhibiting the cytopathic effect and the virus proliferation at least at a concentration of Q4%. This fact indicates that the present invention firstly found the components (especially wheat jaundice) in the extract of the white bamboo extract. It is effective not only for the usual cytomegalovirus, but also for the gluoxivir-resistant virus. The anti-disease table of the extract of the white bamboo extract from the mountain is extracted from the extract of the white bamboo extract. P-coumaric acid

Column 1), vanillin (series 2), p-parabenzaldehyde (series 3), 3_pyridinium (series 4), 5,7,4,-trisyl groups _3,,5, - Dimethoxyflavone (also known as flavonoids) (Series 5). The HCMV proliferation inhibitory effect of each compound is shown in Fig. 3. Further, the relationship between the concentration of the vaginal ketone and the virus titer is shown in Fig. 4. It is understood that when the concentration of flavonoids is m#g/ml, the proliferation of the virus is almost completely suppressed. Further, IC5q (5 〇% inhibitory concentration) (cytotoxicity) U g/ml), EC50 (50% effective concentration) (a g/ml), and SI (selection index) of various compounds are shown in Table 1.

C 320044 19 1363621 [Table 1] Compound IC5〇ec5〇SI p-coumaric acid 187 8.2 22.8 Vanilla awake 215 48.0 4.5 p-Hydroxybenzaldehyde 305 12.8 23.8 3 -Phase alpha ratio bite 263 3.4 77.4 Flavonoid 2050 1.7 1205.8 Gemcyclovir 0.3 to 0.8 As can be seen from Table 1, the compounds of the present invention, especially flavonoids (flavonoids), have a significantly low cytotoxicity and a low effective concentration (high activity), because - The selection index (ic50/ec5〇) was significantly higher. Example 2 (Antiviral action of flavonoids against influenza virus) The antiviral action of flavonoids against influenza virus was investigated according to the following method. Cells: MDCK cell type of influenza virus: A/Hiroshima/52/2005, H3N2 φ B/Malaysia/2506/2004 After each virus was propagated to MDCK cells and the viral power was determined, it was cryopreserved at -80 °C. In the freezer, use it after thawing. Method: Each virus was allowed to adsorb at room temperature for 1 hour in accordance with the usual plaque method, i.e., for MDCK cells which had been cultured in a plastic dish in a 5% carbon dioxide incubator. After removing the unadsorbed virus, 0.6% acacia medium supplemented with trypsin containing various concentrations of flavonoids was added thereto, and the leaves were solidified at room temperature, and then cultured in an incubator with 5% carbon dioxide. day. 20 320044 1363621 • After the culture was completed, the cells were fixed with 1 〇〇/0 ,, the artichokes were removed, and the number of plaques was counted after staining with 〇.〇3°/〇 methylene blue solution. r The number of plaques (pt) of the experimental group to which flavonoids was added was divided by the number of plaques (pc) of the experimental group without flavonoids, and the antiviral effect (increased inhibition rate) was calculated. Tpt/pedOO%). When the concentration of flavonoids was 0.3/zg/ml, the leanness inhibition rate of influenza A virus was 52%, and the proliferation inhibition rate of influenza B virus was 48%. The results are shown in Figure 5. The above results fully demonstrate that buckwheat flavonoids also exhibit high proliferation inhibition effects on the stomach of other influenza viruses such as avian influenza. Formulation Example 1 (Capsule) 250 mg of flavonoids was placed in a capsule to prepare an antiviral agent of the present invention. Formulation Example 2 (tablet) A mixture of malt flakes and lactose was molded and formed into a spinner containing 100 mg of flavonoids. [Simplified illustration] [ [Fig. 1] shows a micrograph of the inhibition of cytopathic effect of virus extract (TWEBS) on viral infections [Fig. 2] shows that white bamboo extract (TWEbS) is for viruses. The inhibition of proliferation. Mapping [Fig. 3] shows the inhibition of virus thinning by the isolated components in the extract of T. chinensis (Fig. 4). The flavonoids (flavonoid derivatives) are shown to be human cytomegalovirus. Inhibition map of proliferation [Fig. 5] shows the inhibition of flavonoids on the proliferation of influenza virus. 320044 1363621 [Description of main components]

Claims (1)

1363621 100. 5. Patent application No. 97109281 TDU year 3 pairs of Japanese amendments Replacement page Year of the month Announcement This book is still filled with ten, the scope of patent application 1. An antiviral agent, which is 5,7,4'-three The hydroxydi-foxy-xanthene is the active ingredient* and the virus is a running virus or an influenza virus. 2. The antiviral agent according to claim 1, wherein the virus is a herpesvirus. 3. The antiviral agent of claim 2, wherein the virus is a cytomegalovirus. 4. The antiviral agent according to claim 2, wherein the virus is a ganciclovir-resistant cytomegalovirus. 5. The antiviral agent of claim 2, wherein the virus is a human cytomegalovirus. 6. The antiviral agent of claim 1, wherein the virus is an influenza virus. 7. The antiviral agent according to claim 1, wherein the virus is a type A influenza virus or a type B influenza virus. 8. The antiviral agent of claim 6, wherein the virus is an avian influenza virus. 23 320044 Amendment